Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.51
-6.9%
$7.81
$1.95
$12.43
$7.87B0.0124.72 million shs8.84 million shs
Insmed, Inc. stock logo
INSM
Insmed
$106.64
-1.8%
$105.64
$90.39
$212.75
$23.11B0.783.06 million shs1.77 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$58.07
-2.7%
$58.13
$22.28
$85.60
$23.04B0.949.04 million shs3.77 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$34.91
-0.1%
$31.90
$10.90
$37.00
$25.11B1.116.00 million shs3.40 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+7.74%+2.41%+9.65%0.00%+201.12%
Insmed, Inc. stock logo
INSM
Insmed
+1.50%-1.35%+13.50%-24.82%+5.68%
Moderna, Inc. stock logo
MRNA
Moderna
+0.29%-11.54%-6.72%+7.30%+92.64%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+2.67%+0.14%+11.23%+19.93%+204.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.51
-6.9%
$7.81
$1.95
$12.43
$7.87B0.0124.72 million shs8.84 million shs
Insmed, Inc. stock logo
INSM
Insmed
$106.64
-1.8%
$105.64
$90.39
$212.75
$23.11B0.783.06 million shs1.77 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$58.07
-2.7%
$58.13
$22.28
$85.60
$23.04B0.949.04 million shs3.77 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$34.91
-0.1%
$31.90
$10.90
$37.00
$25.11B1.116.00 million shs3.40 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+7.74%+2.41%+9.65%0.00%+201.12%
Insmed, Inc. stock logo
INSM
Insmed
+1.50%-1.35%+13.50%-24.82%+5.68%
Moderna, Inc. stock logo
MRNA
Moderna
+0.29%-11.54%-6.72%+7.30%+92.64%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+2.67%+0.14%+11.23%+19.93%+204.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$14.2088.70% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$209.1396.09% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.82
Reduce$40.00-31.30% Downside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$33.59-3.50% Downside

Current Analyst Ratings Breakdown

Latest IBRX, MRNA, ROIV, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$49.00 ➝ $67.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
Initiated CoverageOutperform$192.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy$220.00
7/20/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingUnderperform$25.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
UpgradeStrong-Buy
7/17/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingSell (D-)
7/15/2026
Insmed, Inc. stock logo
INSM
Insmed
Boost Price TargetOverweight$160.00 ➝ $161.00
7/10/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Reiterated RatingSell (D-)
7/10/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy$207.00
7/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$33.00 ➝ $39.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$38.00 ➝ $45.00
(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$140.98M55.91N/AN/A($0.51) per share-14.75
Insmed, Inc. stock logo
INSM
Insmed
$819.56M28.21N/AN/A$3.46 per share30.82
Moderna, Inc. stock logo
MRNA
Moderna
$2.20B10.48N/AN/A$22.14 per share2.63
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,031.21N/AN/A$7.35 per share4.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$5.75N/A177.75N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)

Latest IBRX, MRNA, ROIV, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q1 2027
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.33N/AN/AN/A$2.07 millionN/A
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.70N/AN/AN/A$392.53 millionN/A
8/4/2026Q2 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.09N/AN/AN/A$49.20 millionN/A
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.0355N/AN/AN/A$103.10 millionN/A
5/7/2026Q1 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million
5/7/2026Q1 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
6.67
6.66
Insmed, Inc. stock logo
INSM
Insmed
0.80
4.47
4.10
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
18.37
18.37

Institutional Ownership

CompanyInstitutional Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5901.05 billion355.05 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664216.75 million212.20 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860719.27 million641.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$7.51 -0.56 (-6.94%)
Closing price 04:00 PM Eastern
Extended Trading
$7.56 +0.05 (+0.67%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Insmed stock logo

Insmed NASDAQ:INSM

$106.64 -1.98 (-1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$107.00 +0.36 (+0.34%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Moderna stock logo

Moderna NASDAQ:MRNA

$58.07 -1.59 (-2.67%)
Closing price 04:00 PM Eastern
Extended Trading
$58.27 +0.20 (+0.34%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$34.91 -0.05 (-0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$35.78 +0.87 (+2.48%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.